OS Therapies Incorporated

AMEX:OSTX

Biotechnology

Healthcare
$1.15 +5.81%

+$0.10 today

Market cap
$53.83M
Beta
-0.95
P/E (TTM)
-2.0
EPS (TTM)
-$0.91
52W Low $1.15High $2.57

Volume 0.50M

Average 0.71M

OSTX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

OS Therapies IncorporatedAMEX: OSTX

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q1 FY2026 research & development of $7.23M rose 452.0% year over year, behind the +432309.4% change in trailing-twelve-month research & development. Sequentially, it fell 100.0% from the prior quarter. Over 3 fiscal years it compounded at +1606.6% a year.

Context

  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +452.0% toward the trailing-twelve-month pace of +432309.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$7.23M-100.0% QoQ
Last fiscal yearDec 2025
$16.36B+576737.4% YoY
LTMMar 2026
$16.37B+432309.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+452.0%——
1 year+576737.4%——
3-year CAGR+1606.6%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
16.36B USD
Year-over-year change
+576737.4%
4-year CAGR
+831.4%

Research & Development vs competitors

How OSTX compares with its peers on the latest reported figures

  • OSTX's LTM Mar 2026 research & development of $16.37B is the highest of the 9 companies compared; the peer median is $18.97M.
  • Its year-over-year change of +432309.4% is the highest of 8, against a peer median of -39.6%.
  • Over three fiscal years its annual growth of +1606.6% compares with a peer median of -11.9%.
OSTX Competitors Peer median
Research & Development for OSTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OSTXOS Therapies IncorporatedLTM Mar 2026$16.37B +432309.4%+1606.6%—
INKTMiNK Therapeutics, Inc.LTM Mar 2026$6.96B +137771.3%+529.2%—
HOWLWerewolf Therapeutics, Inc.LTM Jun 2026$32.91M -39.6%-5.9%156.7%
ADAGAdagene Inc.LTM Jun 2024$30.07M —-35.3%3686.7%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$21.25M -43.8%+8527.1%6378.2%
SPRBSpruce Biosciences, Inc.LTM Mar 2026$16.69M -64.4%-17.8%—
EQEquillium, Inc.LTM Mar 2026$9.91M -70.5%-30.1%—
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$4.28M -18.5%-39.5%186.8%
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$1.43M -13.1%+294.0%100.9%
Peer median (excluding OSTX) $18.97M-39.6%-11.9%186.8%

Competitors are the stored peer set for OSTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue1.16M8054.22K2.78K363.09K
Gross Profit(1.16M)(805)(4.22K)(2.78K)(363.09K)
Gross Margin—————
Research & Development2.17M3.29M3.22M2.84M16.36B
Selling, General & Admin1.5M1.15M1.12M3.97M12.34B
Operating Expenses3.68M4.45M4.34M6.81M28.34M
Depreciation & Amortization8058054.22K2.78K363.09K
EBITDA(4.84M)(4.45M)(4.34M)(6.83M)(28.39M)
EBITDA Margin—————
Operating Income(4.84M)(4.45M)(4.34M)(6.81M)(28.71M)
Operating Margin—————
Interest Income0000249
Interest Expense2.58M1.81M3.45M2.05M0
Other Income / Expenses(2.58M)(1.81M)(3.45M)(2.07M)(48.14K)
Income Before Tax(7.42M)(6.25M)(7.79M)(8.88M)(28.75M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(7.42M)(6.25M)(7.79M)(8.88M)(28.75M)
Net Margin—————
EPS (Basic)(0.33)(0.28)(0.39)(0.52)(0.98)
EPS (Diluted)(0.33)(0.28)(0.39)(0.52)(0.98)
Weighted Avg Shares23.1M23.1M20.05M20.87M29.25M
Weighted Avg Shares (Diluted)23.1M23.1M20.05M20.87M29.25M

OS Therapies Incorporated

AMEX:OSTX

Intrinsic Alpha fair value

Locked

Current Price

$1.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.